RxDoctor Payments Data

Justin Lege, NP

Nurse Practitioner · Opelousas, LANPI 1164810164

Payments from drug & device makers

$5,342in general payments, 2019–2025

Across 317 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • ANI Pharmaceuticals, Inc.$917
  • Mallinckrodt Hospital Products Inc.$848
  • Vifor Pharma, Inc.$692
  • Fresenius USA Marketing, Inc.$524
  • Otsuka America Pharmaceutical, Inc.$430
  • plus $880 from 11 others

What the payments were for

  • Food & beverage$5,19897%
  • Education$1443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,342 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$16,025
Medicare patients
51
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CortrophinCorticotropin19$659,216
VelphoroSucroferric Oxyhydroxide69$260,806
FarxigaDapagliflozin Propanediol129$93,753
LokelmaSodium Zirconium Cyclosilicate20$24,926
VeltassaPatiromer Calcium Sorbitex12$14,068
Cinacalcet Hcl51$10,218
Sevelamer Carbonate87$8,631
Calcitriol263$3,896
Potassium Chloride229$2,321
Mycophenolate Mofetil11$856
Hydralazine Hcl86$808
Metolazone26$752
Furosemide250$732
Torsemide17$705
Amlodipine Besylate232$629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$524$260,80669 claims
AstraZenecaFarxiga, Lokelma$1,051$118,679149 claims
ANI Pharmaceuticals, Inc.Valsartan$917$43450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →